Abstract
Group B streptococcus (GBS) isolated from human neonates diagnosed with sepsis and respiratory distress produces a polysaccharide exotoxin (CM101) which has been previously described as GBS toxin. CM101 infused i.v. into tumor-bearing mice causes rapid tumor neovascularitis, infiltration of inflammatory cells, inhibition of tumor growth and tumor apoptosis. CM101 has successfully completed phase I studies in refractory cancer patients with very encouraging results. We have now demonstrated a mechanism of action for CM101. Using a normal mouse tumor model, we have examined tumor and normal tissues which were harvested at 0, 5, 15, 30 and 60 min post-infusion of either CM101 or dextran. We present evidence that CM101 is rapidly (within the first 5 min) bound to the tumor neovasculature. Complement is activated by the alternative pathway (C3) and leukocytes start to infiltrate the tumor within the first 5 min. Through RT-PCR and immunohistochemical techniques, we demonstrate that proinflammatory cytokines, interleukin-6 and tumor necrosis factor (TNF)-α, are up-regulated in infiltrating leukocytes and TNF receptor 2 is up-regulated in the targeted tumor neovasculature. Combined, these events constitute possible explanations for the observed pathophysiology of tumor ablation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hellerqvist CG, Rojas J, Green RS, et al.Studies on group B β-hemolytic streptococcus. I. Isolation and partial characterization of an extracellular toxin. Pediatr Res1981; 15, 892–898.
Rojas J, Green RS, Hellerqvist CG, et al.Studies on group B b-hemolytic streptococcus. II. Effects on pulmonary hemo-dynamics and vascular permeability in unanesthetized sheep. Pediatr Res1981; 15, 899–904.
Sandberg K, Edberg KE, Fish W, et al.Thromboxane receptor blockage (SQ 29548) in group B streptococcal (GBS) toxin challenge in young lambs. Pediatr Res1994; 35, 571–579.
Rojas J, Larrson LE, Hellerqvist CG, et al.Pulmonary hemodynamic and ultrastructural changes associated with group B b-hemolytic streptococcal toxemia in adult sheep and newborn lambs. Pediatr Res1983; 17, 1002–1008.
Hellerqvist CG. Therapeutic agent and method of inhibiting vascularization of tumors. US Patent 5,010,062, April 23, 1991.
Sundell HW, Yan H-P, Wu K, et al.Isolation and identification of group B beta-hemolytic streptococcal (GBS) toxin from septic newborn infants. Pediatr Res1997; 39, 302A.
Hellerqvist CG, Thurman GB, Page DL, et al.Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B b-hemolytic streptococcus. J Cancer Res Clin Oncol1993; 120, 63–70.
Thurman GB, Russell BA, York GE, et al.Effects of GBS toxin on long-term survival of mice bearing transplanted Madison lung tumors. J Cancer Res Clin Oncol1994; 120, 479–484.
Hellerqvist CG, Thurman GB, Russell BA, et al.Anti-tumor effects of GBS toxin are caused by induction of a targeted inflammatory reaction. In: Maragoudakis ME, Gullino PM, Lelkes PI, eds. NATO/ASI Series — Angiogenesis: Molecular Biology, Clinical Aspects, Series A: Life Sciences. New York: Plenum 1993; 263, 265–269.
Thurman GB, Page DL, Wamil BD, et al.Acute inflammatory changes in subcutaneous microtumors in mice ears induced by intravenous CM101 (GBS toxin). J Cancer Res Clin Oncol1996; 122, 549–553.
DeVore RF, Hellerqvist CG, Wakefield GB, et al.A phase I study of the antineovascularization drug CM101. J Clin Cancer Res1997; 3, 365–372.
Wamil BD, Thurman GB, DeVore RF, et al.Soluble e-Selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor inhibiting agent, evaluated in phase I clinical trial. J Cancer Res Clin Oncol1997; 123, 173–179.
Vetvicka V, Thornton BP, Ross GD. Soluble betaglucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest1996; 98, 50–61.
Hellerqvist CG, Lloyd S, Wang E, et al.Modulation of interleukin-12 mRNA expression in leukocytes of cancer patients treated with CM101. Ann NY Acad Sci1995; 795, 346–348.
Fu C, Carter CE. Detection of circulating antigen in human schistosomiasis japonica using monoclonal antibody. Am J Trop Med Hyg1990; 42, 347–351.
Oncor. In Situ Apoptosis Detection1994.
Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning-A Laboratory Manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press 1989: 10.51–10.69.
Liszewki KM, Atkinson JP. The complement system. In: Paul WE, ed. Fundamental Immunology, New York: Raven Press, 1993: 917–939.
Ochs HD, Nonoyama S, Zhu Q, et al.Regulation of antibody responses: the role of complement and adhesion molecules. Clin Immunol Immunopathol1993; 67, 33–40.
Ward PA. Role of complement, chemokines and regulatory cytokines in acute lung injury (Review). Ann NY Acad Sci1996; 796, 104–112.
Parkinson DR. Present status of biological response modifiers in cancer. Am J Med1995; 99, 545.
Donato NJ and Perez M. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and-21 WAF1 proteolysis in ME-180 cells. J Biol Chem1998; 273, 5067–5072.
Hellerqvist CG, Wang E, Wamil BD, et al.Evidence of induced apoptosis in cancer patients treated with CM101. Proc Am Soc Clin Oncol1997; 16, 546a.
Hellerqvist CG, Yan HP, Carter CE, et al.Identification of GBS toxin in neonatal fluids from group B streptococcus (GBS) infected neonates. Proc Am Soc Microbiol1996; B-348, 215.
Hellerqvist CG, Yan HP, Carter CE, et al.CM101 induces a complement-activated inflammatory response targeting tumor neovasculature. Proc Am Ass Cancer Res1996; 73, 487 (abstr 3328).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yan, HP., Carter, C.E., Wang, Ez. et al. Functional studies on the anti-pathoangiogenic properties of CM101. Angiogenesis 2, 219–233 (1998). https://doi.org/10.1023/A:1009258801899
Issue Date:
DOI: https://doi.org/10.1023/A:1009258801899